EDN1 and coronary artery disorder: Dai et al. recently reported that alpinetin (40–160 mg/kg) notably attenuated left ventricular end-diastolic volume (LVEDV), inhibited serum triglyceride (TG), endothelin-1 (ET-1) and TNF-α production, upregulated NO expression, and finally improved heart function in CHD rat model through suppressing MEK/ERK signaling pathway (Dai et al., 2021).